



**Outpatient Medical Injectable
Granulocyte Colony-Stimulating Factors
Request Form
Fax to 833-619-5745
(Medical Benefit Only)**

Member Name: _____

Member Date of Birth: _____

Member UMI: _____ Medicare Commercial

Requesting Physician's Name: _____ NPI Number: _____

Requesting Physician's Address: _____

Office Contact: _____ Phone #: _____ Fax #: _____

Facility: _____ Facility NPI Number: _____

Facility's Address: _____

Date of Service: _____

Diagnosis Code(s): _____

DRUG INFORMATION (please select one)	
<p><u>PREFERRED PRODUCTS</u></p> <p><input type="checkbox"/> Neulasta (J2506)</p> <p><input type="checkbox"/> Fulphila (Q5108)</p> <p><input type="checkbox"/> Ziextenzo (Q5120)</p>	<p><u>NON-PREFERRED**</u></p> <p><input type="checkbox"/> Udenyca (Q5111) <input type="checkbox"/> Stimufend (_____)</p> <p><input type="checkbox"/> Nyvepria (Q5120) <input type="checkbox"/> Fylnetra (_____)</p> <p><input type="checkbox"/> Rolvedon (_____)</p> <p><small>**A non-preferred product will be considered when the member has documented therapy failure after an adequate therapeutic trial of a preferred product, or the preferred product has not been tolerated or is contraindicated</small></p> <p><small>**Medicare members currently established on a non-preferred therapy are not required to try a preferred option</small></p>
<p>1. What is the member's cancer diagnosis and staging?</p>	

****Please verify member's eligibility and benefits through the health plan****

Fax this completed form to Highmark at 1-833-619-5745

Highmark Blue Cross Blue Shield of Western New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association.

2. Is this medication being used to prevent chemo-induced febrile neutropenia? <i>(If NO, please state intended use)</i>	<input type="checkbox"/> YES <input type="checkbox"/> NO
3. What is the member's complete chemo regimen?	
4. Is the member considered to be at low, intermediate, or high risk for febrile neutropenia?	<input type="checkbox"/> Low <input type="checkbox"/> Intermediate <input type="checkbox"/> High
5. Is the member at an increased risk for febrile neutropenia due to any of the following reasons?	<input type="checkbox"/> Persistent neutropenia (ANC of 1500/mm ³ or less) <input type="checkbox"/> History of febrile neutropenia <input type="checkbox"/> Prior exposure to chemotherapy or radiation <input type="checkbox"/> Bone marrow involvement by tumor <input type="checkbox"/> Recent surgery and/or open wounds <input type="checkbox"/> Liver or renal dysfunction <input type="checkbox"/> Age > 65 years receiving full chemo dose intensity <input type="checkbox"/> Comorbidities that can increase risk of serious infection <input type="checkbox"/> Other:

<p>Please attach all pertinent clinical information</p> <p>Attached: <input type="checkbox"/> YES <input type="checkbox"/> NO</p>
--

****Please verify member's eligibility and benefits through the health plan****

Fax this completed form to Highmark at 1-833-619-5745

Highmark Blue Cross Blue Shield of Western New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association.